Study: Many Thyroid Cancer Patients Say They Had No Choice About Radioactive Iodine

Better shared decision-making could help patients feel more empowered, avoid treatment side-effects and reduce overtreatment.

5:00 PM

Author | Ian Demsky

Doctor Office

After thyroid cancer surgery, many patients should be in the position of deciding with their doctors whether to pursue treatment with radioactive iodine to help ease long-term follow-up and offer reassurance that the cancer is gone.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily updates on iTunesGoogle Playand Stitcher.

A new survey by researchers at the University of Michigan Rogel Cancer Center and U-M Institute for Healthcare Policy and Innovation suggests many patients are receiving the treatment when there's no strong indication of benefit — and a majority may feel like they don't really have a choice about it.

"If these patients are empowered to have more say in whether they receive radioactive iodine, one, it might decrease overtreatment and, two, there might be more long-term patient satisfaction with their outcomes and their choices — especially given the burdens that side effects and treatment costs can have," says study senior author Megan Haymart, M.D., a clinician and health services researcher at Michigan Medicine.

The research team's findings appear in the Journal of Clinical Oncology.

Selective use recommended for most patients

Clinical guidelines recommend radioactive iodine for the highest risk patients, and recommend against it for the lowest risk patients. But most patients fall somewhere in the middle, where more cautious, case-by-case decision-making is recommended, Haymart explains. This places the responsibility for whether to pursue the treatment squarely on the shoulders of doctors and their patients.

In the study sample of more than 1,300 of these middle-ground patients, the researchers found that 76% received radioactive iodine and more than half felt they weren't given a choice in the matter.

The patients were identified using the National Cancer Institute Surveillance, Epidemiology, and End Result registries in California and Georgia.

"In our prior work, we found that there's wide variation in the use of radioactive iodine," says Haymart, associate professor of medicine. "And in some instances we found more aggressive use or more intensive use than would be recommended by the guidelines.

"So, we wanted to look specifically at the patients' role in decision making," she says. "In this group of patients for whom selective use is recommended — where there should be a conversation between the patient and physician — did they feel they had a choice as to whether or not they received radioactive iodine? And, unfortunately, the answer is that many did not."

Patients' perception of not having a choice was associated both with greater receipt of the treatment, as well as with lower satisfaction with the decision after the fact, even when adjusting for treatment-related side effects, notes study first author Lauren Wallner, Ph.D., M.P.H., assistant professor of medicine at Michigan Medicine.

[Patients] should ask what the side effects of this treatment are likely to be. And what the doctor expects to be different in regard to outcome if they receive the treatment or if they decide not to pursue the treatment,
Megan Haymart, M.D.

Long-term side effects from radioactive iodine treatment can impact patients' quality of life, Haymart says. The biggest issue is damage to patients' salivary glands and tear ducts caused by the radiation. The most commonly reported symptoms include swelling and tenderness of the salivary glands, dry mouth, increased dental cavities and excess tearing due to tear duct obstructions.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

Patients may also briefly experience side effects leading up to and shortly after treatment. They may be placed on low-iodine diets that require cutting down or avoiding foods like dairy, fish and green vegetables. They also have to stop taking thyroid hormone replacement or receive injections of thyrotropin alfa (Thyrogen) prior to radioactive iodine treatment. During the period when they are off thyroid hormone replacement, patients may experience fatigue, mental slowing and weight gain. However, after radioactive iodine treatment is complete, thyroid hormone replacement is restarted and these symptoms typically resolve.

Recommendations for patients and doctors

Why are such a large percentage of patients receiving iodine treatment? Several factors may be at play, Haymart says. One is historical precedent. For many years, radioactive iodine was a standard treatment for most thyroid cancer patients — until outcomes data cautioned that a less aggressive approach might be appropriate for those outside of the highest-risk categories.

SEE ALSO: Reducing Overtreatment in Cancer Patients: When Is Active Surveillance Appropriate?

Another might be a form of confirmation bias: If a doctor gives a treatment and their patient does well, it's easy to believe that the patient did well because of the treatment — even if they might have done equally well without it.

Haymart says it's important for patients to ask their doctors about the potential benefits and risks of radioactive iodine treatment.

"They should ask what the side effects of this treatment are likely to be," she says. "And what the doctor expects to be different in regard to outcome if they receive the treatment or if they decide not to pursue the treatment."

On the physician side, Haymart cautions against a one-size-fits-all approach.

"Doctors should take into account the individual patient, their perspectives and their disease severity, and work with the patients to make these decisions," she says. "Especially in cases such as this where there's not great data on benefit and there are known risks, the patient needs to be fully aware of both the benefits and the risks, and be empowered to have a say in whether treatment occurs."


More Articles About: Health Tech Cancer Treatment Cancer Research Thyroid Cancer Cancer: Help, Diagnosis & Treatment
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Health care provider with stethoscope holds patient's hand
Health Lab
Combatting prostate cancer stigma
Prostate cancer is highly treatable and over 98% of men survive 10 years if the cancer is diagnosed and treated early.
Woman in pink shirt lifts kettleball in an outdoor exercise class
Health Lab
How to make cancer prevention more equitable
Expert explains six behavioral risk factors for cancer and why current programs don’t always meet the needs of people from racially and ethnically minoritized groups and other vulnerable populations.
Illustration of a doctor and patient looking at ultrasound
Health Lab
Novel device detects cervix “ripening” to predict normal and abnormal labor
Multi-specialty team is studying a non-invasive method to measure underlying cervical tissue changes that precede birth with the hopes of predicting timing of birth.
Portrait of Max Wicha, founding director of Rogel Cancer Center
Health Lab
‘We might for the first time really be thinking of cures of cancer’
Founding Rogel Cancer Center Director reflects on how cancer evolved from ‘the least scientific discipline’ to a shining example of how basic research discoveries can change clinical care.
Don Reynolds, seated at right, and his family gather together. Reynolds can garden with his grandchildren after a successful treatment with Pluvicto. Photos courtesy of the Reynolds family
Health Lab
Pluvicto treatment gives patient another chance
New treatment for metastatic castration resistant prostate cancer helped patient get back to his hobbies
colorful drawing of people figures dark background
Health Lab
Everyone plays a role in improving cancer health equity
As guest editor for a themed journal issue, Lori Pierce helps highlight the multiple factors that can make cancer care and prevention more equitable and reduce the burden of this disease for all